The cord blood banking industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.
While it may be possible to stay informed about cord blood industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant cord blood industry events for July 2015.
Cord Blood News Round-Up for July 2015
Artificial Blood Transfusion To Soon Become A Reality
[July 2, 2015] The first human trial of artificial blood, manufactured using stem cells from adult and umbilical cord blood, is all set to be carried out in the UK by 2017, according to the NHS Blood and Transplant.
Americord Registry, Smart Cells International partner to educate parents on benefits of cord blood banking
[June 26, 2015] Conducting their respective operations in different regions of the world, Americord and Smart Cells represent two pillars of a global industry that is growing each year. “We are excited about our partnership with Smart Cells International,” said Martin Smithmyer, CEO of Americord. “Our aligned mission to provide parents with both the information they need and the highest quality stem cell banking service means that we can further a culture of transparent, trustworthy cord blood banking for all families.”
The role and potential of umbilical cord blood in an era of new therapies: a review
[July 2, 2015] This review discusses many issues surrounding the conservation of UCB-derived cells and the great potential and current clinical applications of UCB in an era of new therapies. In particular, we describe the practical issues inherent in UCB collection, processing, and long-term storage as well as the different types of ‘stem’ or progenitor cells circulating in UCB and their uses in multiple clinical settings.
Services and Research Collaboration Agreement between CellResearch Corporation Pte Ltd and the University of Colorado School of Medicine
[June 16, 2015] The Service and Research Collaboration Agreement has the objective of achieving US FDA approval for therapeutic products of Umbilical Cord Lining Membrane Progenitor/Stem cells. This first collaboration will focus on the development of CRC’s proprietary and patented Cord Lining Mesenchymal Stem Cells for the Treatment of Diabetic Wounds. Under the agreement, UC SOM and CIL will initially provide technical and clinical guidance for the production and testing of a cell bank of CRC’s mesenchymal stem cells.
Isolation of mesenchymal stromal/stem cells from small-volume umbilical cord blood units that do not qualify for the banking system
[June 30, 2015] In this study, we examined the availability of freshly donated umbilical cord blood (UCB) units that do not qualify for the Japanese banking system for transplantation because of their small volume as a source of MSCs.
Supporting Effect of Umbilical Cord Blood-Derived Mesenchymal Stem Cells on CD34(+) Cell Proliferation and Its Mechanism
[June 23, 2015] Xu et al. concluded that UCB-derived MSCs as a feeder layer can be an alternative approach for ex vivo expansion of HSCs, and the cytokines by secreted UCB-MSCs may mediate the suppor-tive role of MSC to HSC proliferation.
Americord Registry Considering Strategic Options
[July 8, 2015] Americord Registry, one of the fastest growing umbilical cord blood, cord tissue and placental tissue stem cell banks in the U.S., announced that it is maintaining strong growth in 2015 after an unsolicited takeover proposal earlier this year.
To learn more about key market news for the cord blood banking industry, view the “Complete 2015-16 Global Cord Blood Banking Industry Report” now.
Or, to receive future cord blood industry news round-ups, sign-up below.
BioInformant is the only research firm that has served the cord blood sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, and the California Institute for Regenerative Medicine (CIRM). Click here to learn more.